BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off patent drug for a new application.

BioMark's team recently published an article titled "Versatility of Amantadine and Rimantadine for Detection of Cancer" in Novel Advances in Cancer with citation: Bram Ramjiawan, Andrew W Maksymiuk, Rashid Ahmed Bux, Tappia Paramjit S, et al. Versatility of Amantadine and Rimantadine for Detection of Cancer. Nov Appro in Can Study. 4(4). NACS.000591. 2020. DOI: 10.31031/NACS.2020.04.000591.

The article is posted on BioMark's website: https://www.biomarkdiagnostics.com/publications-scientific-posters/

"The publication further demonstrates the versatility of BioMark's SSAT cancer diagnostic platform that uses FDA approved agents and measures with urinary or plasma concentration of the acetylated substrates utilizing our proprietary validated internal laboratory standards," says Rashid Bux, CEO of BioMark Diagnostics. "Our test has multiple clinical applications addressing the most critical issues associated with the disease. BioMark's platform can detect and diagnose the presence of cancer, determining an individual's risk of developing cancer, monitoring response to treatment, and the possible measurement of recurrence for cancer survivors. I believe that this announcement further validates our commitment to investing in science while building and protecting its core cancer technology platform."

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58350

info